MaxCyte
$0.74
20
+$0.04+5.92% Wednesday 20:00
Statistics
Day High
0.76
Day Low
0.69
52W High
2.96
52W Low
0.64
Volume
1,505,732
Avg. Volume
1,132,881
Mkt Cap
79.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.072525
Actual EPS
N/A
Financials
-106.29%Profit Margin
Unprofitable77.25MRevenue
-82.11MNet Income
Analyst Ratings
$5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MXCT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Danaher
DHR
Mkt Cap152.13B
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Illumina
ILMN
Mkt Cap18.99B
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Editas Medicine
EDIT
Mkt Cap276.95M
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
About
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Show more...
CEO
Mr. Maher Masoud
Employees
114
Country
US
ISIN
US57777K1060
Listings
0 Comments
Share your thoughts
FAQ
What is MaxCyte stock price today?▼
The current price of MXCT is $0.74 USD — it has increased by +5.92% in the past 24 hours. Watch MaxCyte stock price performance more closely on the chart.
What is MaxCyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MaxCyte stocks are traded under the ticker MXCT.
Is MaxCyte stock price growing?▼
MXCT stock has risen by +3.19% compared to the previous week, the month change is a -5.58% fall, over the last year MaxCyte has showed a -73.04% decrease.
What is MaxCyte market cap?▼
Today MaxCyte has the market capitalization of 79.38M
When is the next MaxCyte earnings date?▼
MaxCyte is going to release the next earnings report on May 13, 2026.
What were MaxCyte earnings last quarter?▼
MXCT earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.08 USD resulting in a -17.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MaxCyte revenue for the last year?▼
MaxCyte revenue for the last year amounts to 77.25M USD.
What is MaxCyte net income for the last year?▼
MXCT net income for the last year is -82.11M USD.
How many employees does MaxCyte have?▼
As of April 02, 2026, the company has 114 employees.
In which sector is MaxCyte located?▼
MaxCyte operates in the Health Care sector.
When did MaxCyte complete a stock split?▼
MaxCyte has not had any recent stock splits.
Where is MaxCyte headquartered?▼
MaxCyte is headquartered in Rockville, US.